{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:31:36Z","timestamp":1792657896262,"version":"4.5.0"},"reference-count":14,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.<\/jats:p>","DOI":"10.1371\/journal.pone.0242184","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T18:40:53Z","timestamp":1605120053000},"page":"e0242184","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients"],"prefix":"10.1371","volume":"15","author":[{"given":"Daniel","family":"Camprub\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4643-4456","authenticated-orcid":true,"given":"Alex","family":"Almuedo-Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-205X","authenticated-orcid":true,"given":"Helena","family":"Mart\u00ed-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-6082","authenticated-orcid":true,"given":"Juan Carlos","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6246-8501","authenticated-orcid":true,"given":"Carme","family":"Subir\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-0965","authenticated-orcid":true,"given":"Berta","family":"Grau-Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-1211","authenticated-orcid":true,"given":"Alejandro","family":"Krolewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"pone.0242184.ref001","author":"The RECOVERY Collaborative Group","journal-title":"New Engl J Med"},{"key":"pone.0242184.ref002","article-title":"Remdesivir for the treatment of Covid-19\u2014preliminary report","author":"JH Beigel","year":"2020","journal-title":"New Engl J Med"},{"key":"pone.0242184.ref003","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","author":"JM Sanders","year":"2020","journal-title":"JAMA"},{"key":"pone.0242184.ref004","first-page":"104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"2020","author":"L Caly","journal-title":"Antiviral Res."},{"key":"pone.0242184.ref005","first-page":"1","article-title":"Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency","author":"C Chaccour","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pone.0242184.ref006","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.16-0923","article-title":"Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries","volume":"97","author":"A Requena-M\u00e9ndez","year":"2017","journal-title":"Am J Trop Med Hyg."},{"issue":"4","key":"pone.0242184.ref007","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dkz524","article-title":"Safety of high-dose ivermectin: a systematic review and meta-analysis","volume":"75","author":"M Navarro","year":"2020","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"pone.0242184.ref008","doi-asserted-by":"crossref","first-page":"e0006020","DOI":"10.1371\/journal.pntd.0006020","article-title":"Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers","volume":"12","author":"J Mu\u00f1oz","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0242184.ref009","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciy246","article-title":"Efficacy and safety of ivermectin against Trichuris trichiura in preschool-aged and school-aged children: a randomized controlled dose-finding trial","volume":"67","author":"D Wimmersberger","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0242184.ref010","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","article-title":"Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial","volume":"19","author":"D Buonfrate","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0242184.ref011","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/cid\/ciy1063","article-title":"Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial)","volume":"69","author":"MR Smit","year":"2019","journal-title":"Clin Infect Dis."},{"key":"pone.0242184.ref012","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.trstmh.2003.10.018","article-title":"Adverse systemic reactions to treatment of onchocerciasiswith ivermectin at normal and high doses given annually or three-monthly","volume":"98","author":"J Kamgno","year":"2004","journal-title":"Trans R Soc TropMed Hyg"},{"key":"pone.0242184.ref013","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002401382731","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"CA Guzzo","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"pone.0242184.ref014","first-page":"1, 469","article-title":"Ivermectin as a potential COVID-19 treatment from a pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens","volume":"34","author":"G Momekov","journal-title":"Biotechnology & Biotechnological Equipment"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0268667","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T18:41:12Z","timestamp":1605120072000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242184"}},"subtitle":[],"editor":[{"given":"Thomas P.C.","family":"Dorlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0242184","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0268667","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]}}}